Cardiovascular Business - November/December 2008 - (Page 29)

clinical ver satility + predictable perfor mance PATHWAY PV™ ATHERECTOMY SYSTEM and colleagues from Sao Paulo University School of Medicine, Brazil, and Johns Hopkins University in Baltimore used the AutoPulse to measure the peak force generated with compression and the pressure generated by the compression (Resuscitation 2004;[61]:273-280). Researchers found that the device generated a greater peak force (mean 125 kg) than manual CPR (51 kg). The mechanical device, however, distributed its force across the chest more uniformly, thereby, reducing the risk of injury. The mean force measured at the sternum for AutoPulse was 203 mmHg, while for manual CPR it was 1381 mmHg. Bela Merkely, MD, director of the Cardiovascular Center at Semmelweis University in Budapest, Hungary, and colleagues perform about 2,500 PCIs a year, with approximately 1,500 of them being acute. Among the high-risk patients, many have cardiogenic shock and many are operated on after successful resuscitation. Within the last year and a half, interventional cardiologists have used the AutoPulse in nearly 100 cases. Some of the benefits of using the device are that the design allows effective compression on a cath lab table; it safeguards the staff from x-ray exposure; it maintains the integrity of the sterile working area; and there are no compromises between PCI and other actions, according to Merkely. As Grogaard et al put it, “Mechanical chest compression devices have shown encouraging results…. An early revascularization strategy would, therefore, seem reasonable, if ischemia is suspected, in a cardiac arrested patient with prolonged unsuccessful [advance cardiac life support].” (J Am Coll Cardiol 2007;50(11):1093-4) proven solutions for challenging lesions + Thrombus + Calcium + Fibrotic lesions + CTO + Long diffuse disease Indications for Use: The Pathway PV™ Atherectomy System is intended for use in atherectomy of the peripheral vasculature. It is not intended for use in coronary, carotid, iliac or renal vasculature. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. + Active Aspiration Actively removes atherosclerotic plaque and minimizes the risk of distal embolization. + Expandable Cutting Tip Blades expand from 2.1 mm to 3.0 mm to allow clinicians to treat from the SFA to below-the-knee. + Differential Cutting Blades Preferentially cuts plaque, calcium, and thrombus. More elastic material will deﬂect away from the blades. For more information about Jetstream™ visit www.pathwaymedical.com or call 425-636-4000 0021-08 Rev A CardiovascularBusiness.com http://www.pathwaymedical.com http://www.pathwaymedical.com http://www.CardiovascularBusiness.com

Table of Contents Feed for the Digital Edition of Cardiovascular Business - November/December 2008

Cardiovascular Business - November/December 2008 Contents First Word Cover Story: Practice Management Software Moves Beyond Bean Counting The Death of CME as We Know It? Clinical Study Digets: Triple-Antiplatelet Therapy; Ex-Vioxx Users Beware Shockwaves Subside from the FDA's Echo Contract Warning Burning Question: Does Laser Heart Therapy for Angina Really Work? Advanced Visualization Adds New Practive Dimension Coronary Calcium Scoring Program Reaps Dividends Interventionalists Get Pumped Up About Mechanical Chest Compression Trials Force Physicians to Re-Examine Oral Anti-Diabetic Drug Protocols News & Views Calendar Reader Resources The ACC Corner

Cardiovascular Business - November/December 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.